摘要
目的观察培菲康及乳果糖口服液对亚临床肝性脑病患者数字连接试验及血氨、肝功能的治疗效果。方法 60例患者分为治疗组及对照组,对照组采取基础治疗,包括合理饮食,服用复合维生素B,益肝灵等。治疗组在对照组治疗的基础上应用培菲康胶囊及乳果糖口服液,二者分别于4周后观察数字连接试验及血氨、肝功能。结果 4周后治疗组及对照组差异有统计学意义(P<0.05),但肝功能改善方面未见差异。结论培菲康联合乳果糖口服液能改善亚临床肝性脑病患者的临床试验指标,对于预防其发展为肝性脑病有重要意义。
Objective To observe Pachycondyla Fei Kang and areola fructose oral liquid for subclinical patients with hepatic encephalopathy blood ammonia,liver function therapeutic effect.Methods Totally 60 patients were divided into treatment group and control group,and the control group,use Multivitamin B etc liver protection medicine treatment.The treatment group using Pachycondyla fe Kang capsule and areola fructose oral liquid,both respectively on four weeks after observing blood ammonia,hepatic function.Results Four weeks later treatment group and control group were significant differences,but liver improvement no differences.Conclusions Pachycondyla milk mixture can improve subclinical patients with hepatic encephalopathy clinical trials index,to prevent its development for hepatic encephalopathy.
出处
《医药论坛杂志》
2011年第3期68-69,共2页
Journal of Medical Forum
关键词
亚临床肝性脑病
乳果糖
培菲康
血氨
Subclinical hepatic encephalopathy
Milk fructose
Pachycondyla fei kang
Blood ammonia
